This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Skinner-Adams, T. S.
Right arrow Articles by Gardiner, D. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Skinner-Adams, T. S.
Right arrow Articles by Gardiner, D. L.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 2007, p. 759-762, Vol. 51, No. 2
0066-4804/07/$08.00+0     doi:10.1128/AAC.00840-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Synergistic Interactions of the Antiretroviral Protease Inhibitors Saquinavir and Ritonavir with Chloroquine and Mefloquine against Plasmodium falciparum In Vitro{triangledown}

T. S. Skinner-Adams,1,2* K. T. Andrews,2 L. Melville,2 J. McCarthy,2 and D. L. Gardiner2

University of Queensland, Department of Medicine, Central Clinical Division, Brisbane 4072, Australia,1 Queensland Institute of Medical Research and Australian Centre for International and Tropical Health and Nutrition, 300 Herston Road, Herston, Queensland 4029, Australia2

Received 11 July 2006/ Returned for modification 1 September 2006/ Accepted 30 October 2006

The antimalarial activity of several antiretroviral protease inhibitor combinations was investigated. Data demonstrate that ritonavir and saquinavir behave synergistically with chloroquine and mefloquine. These data, and interactions with pepstatin-A, E-64, and bestatin, suggest that human immunodeficiency virus protease inhibitors do not target digestive-vacuole plasmepsins.

* Corresponding author. Mailing address: Malaria Biology Laboratory, Infectious Diseases and Immunology Division, Queensland Institute of Medical Research, Herston, QLD 4029, Australia. Phone: 61 07 3362 0419. Fax: 61 07 3362 0104. E-mail: tinaS{at}qimr.edu.au.

{triangledown} Published ahead of print on 6 November 2006.

Antimicrobial Agents and Chemotherapy, February 2007, p. 759-762, Vol. 51, No. 2
0066-4804/07/$08.00+0     doi:10.1128/AAC.00840-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Lek-Uthai, U., Suwanarusk, R., Ruengweerayut, R., Skinner-Adams, T. S., Nosten, F., Gardiner, D. L., Boonma, P., Piera, K. A., Andrews, K. T., MacHunter, B., McCarthy, J. S., Anstey, N. M., Price, R. N., Russell, B. (2008). Stronger Activity of Human Immunodeficiency Virus Type 1 Protease Inhibitors against Clinical Isolates of Plasmodium vivax than against Those of P. falciparum. Antimicrob. Agents Chemother. 52: 2435-2441 [Abstract] [Full Text]  
  • He, Z., Qin, L., Chen, L., Peng, N., You, J., Chen, X. (2008). Synergy of Human Immunodeficiency Virus Protease Inhibitors with Chloroquine against Plasmodium falciparum In Vitro and Plasmodium chabaudi In Vivo. Antimicrob. Agents Chemother. 52: 2653-2656 [Abstract] [Full Text]  
  • Brentlinger, P. E., Behrens, C. B., Kublin, J. G. (2007). Challenges in the Prevention, Diagnosis, and Treatment of Malaria in Human Immunodeficiency Virus Infected Adults in Sub-Saharan Africa. Arch Intern Med 167: 1827-1836 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»